RLYB

Rallybio Corp

15.54

Oct 30 • 3:59 PM ET +0.13 (0.84%)

15.54

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: OLMA CELC ARVN RLAY STRO INCY ACRV BDTX ZYME PFE

| Held by: VTI VXF IWC DFAS DFMC AVSC DXUV DCOR DFAC

Scroll to Statements

Index	-
Market Cap	83.67M
Enterprise Value	-7.02M
Income	26.81M
Sales	0.43M
Book/sh	17.31
Cash/sh	16.84
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Nov 06, 2026
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Jul 29, 2021

P/E	3.46
Forward P/E	-
PEG	-
P/S	194.58
P/B	0.90
P/C	0.92
P/FCF	2.70
EV/EBITDA	-
EV/Sales	-16.33
Quick Ratio	28.87
Current Ratio	28.87
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	4.49
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	54.34% 24.69%
Sales past 3/5Y	- -
EPS Y/Y TTM	281.10%
Sales Y/Y TTM	-35.61%
EPS Q/Q	-116.77%
Sales Q/Q	-100.00%
Earnings	-
EPS/Sales Surpr.	268.75% 217.84%

Insider Own	23.23%
Insider Trans	31.81%
Inst Own	58.95%
Inst Trans	-28.83%
ROA	32.85%
ROE	34.52%
ROIC	29.05%
Gross Margin	98.16%
Oper. Margin	-4659.22%
Profit Margin	6177.42%
SMA20	-5.79%
SMA50	-7.14%
SMA200	20.19%
Trades

Shs Outstand	5.33M
Shs Float	4.13M
Short Float	0.99%
Short Ratio	2.63
Short Interest	0.04M
52W High	17.57 -11.57%
52W Low	3.67 323.42%
Volatility	5.16% 2.61%
ATR (14)	0.50
RSI (14)	33.81
Beta	-0.74
Rel Volume	3.97
Avg Volume	15.56K
Volume	61,724

Perf Week	-6.61%
Perf Month	-7.28%
Perf Quarter	-2.57%
Perf Half Y	65.14%
Perf YTD	183.12%
Perf Year	178.61%
Perf 3Y	-55.75%
Perf 5Y	-89.12%
Perf 10Y	-
Recom	2.50
Target Price	8.00
Prev Close	15.41
Price	15.54
Change %	0.84%

Consensus

Buy

Avg. Price Target

$8.00

Implied Upside

-48.5%

Analysts7incl. previous ratings

Rating Distribution4 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 09, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral
May 15, 2024	Downgrade	JJP Morgan	Overweight → Neutral
Feb 07, 2024	Downgrade	JJefferies	Buy → Hold	$7 → $1.50	-90.3%
Apr 17, 2023	Initiated	HH.C. Wainwright	Buy	$18	+15.8%
Apr 10, 2023	Initiated	WWedbush	Outperform	$17	+9.4%
Dec 09, 2022	Initiated	JJP Morgan	Overweight	$21	+35.1%
Feb 22, 2022	Initiated	JJMP Securities	Mkt Outperform	$32	+105.9%
Aug 23, 2021	Initiated	JJefferies	Buy	$20	+28.7%
Aug 23, 2021	Initiated	EEvercore ISI	Outperform	$40	+157.4%
Aug 23, 2021	Initiated	CCowen	Outperform

Jul-21-26 02:53PM	Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-24-26 02:15PM	VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development (Exec Edge)
Jun-22-26 11:40AM	Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing (Exec Edge)
Jun-09-26 01:19PM	Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-01-26 12:26PM	RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo How Much Of The New Company Will Rallybio Shareholders Own? (Stocktwits) +16.67%
11:03AM	Loading…
11:03AM	RallyBio tries again for reverse merger, this time with Avenzo (BioPharma Dive)
08:00AM	Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement (Business Wire)
Apr-09-26 03:29PM	Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Apr-06-26 02:38PM	Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders? (PR Newswire)
Mar-06-26 11:15AM	Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? (PR Newswire)
Mar-03-26 07:20AM	Rallybio to acquire Candid Therapeutics (Pharmaceutical Business Review)
Mar-02-26 03:56PM	Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders? (PR Newswire) +45.49%
10:51AM	Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism (Benzinga)
08:00AM	Rallybio Corporation and Candid Therapeutics Announce Merger Agreement (Business Wire)
06:05AM	Candid, in a reverse merger with RallyBio, to go public (BioPharma Dive)
10:46AM	Loading…
Feb-17-26 10:46AM	Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 (Benzinga) -10.17%
08:00AM	Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement (Business Wire)
Feb-04-26 10:05AM	Stock Splits Matter: Whats Coming Up This Month? (24/7 Wall St.) -8.12%
Feb-03-26 04:05PM	Rallybio Announces Reverse Stock Split of Common Stock (Business Wire)
Nov-06-25 08:00AM	Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Sep-25-25 08:00AM	Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study (Business Wire)
Sep-03-25 08:00AM	Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program (Business Wire)
Aug-07-25 08:00AM	Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Aug-05-25 06:30AM	Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-21-25 12:14AM	Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia (Insider Monkey) +7.51%
Jul-09-25 11:56AM	RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program (Zacks) -12.71%
08:16AM	Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M (TipRanks)
07:18AM	Rallybio sells REV102 programme to Recursion for up to $25m (Pharmaceutical Business Review)
Jul-08-25 01:28PM	Here's Why Shares in Recursion Pharmaceuticals Surged Today (Motley Fool) +50.24%
08:00AM	Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia (GlobeNewswire)
08:00AM	Loading…
08:00AM	Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals (Business Wire)
Jul-07-25 09:00AM	ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors (Business Wire)
Jun-12-25 08:00AM	Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study (Business Wire) -7.30%
May-08-25 08:00AM	Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Apr-29-25 08:00AM	Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference (Business Wire)
Apr-09-25 10:58AM	RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks (Zacks)
07:21AM	Rallybio drops drug for rare maternal disorder following Phase II fail (Clinical Trials Arena)
Apr-08-25 08:00AM	Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT (Business Wire) -41.16%
05:27AM	Rallybio discontinues lead drug for rare maternal disorder (BioPharma Dive)
Mar-13-25 08:00AM	Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (Business Wire)
Feb-25-25 08:00AM	Rallybio to Present at the TD Cowen 45th Annual Health Care Conference (Business Wire) -6.30%
Feb-12-25 05:29AM	Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe (Clinical Trials Arena)
Feb-11-25 08:00AM	Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial (Business Wire)
Jan-10-25 08:00AM	Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025 (Business Wire) -5.63%
Dec-10-24 08:00AM	Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting (Business Wire)
Dec-06-24 06:48AM	Rallybio price target lowered to $7 from $8 at JMP Securities (TipRanks)
Dec-02-24 08:00AM	Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 (Business Wire)
Nov-27-24 08:00AM	Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women (Business Wire)
Nov-26-24 08:00AM	Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference (Business Wire)
Nov-25-24 08:00AM	Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor (Business Wire)
Nov-22-24 07:01AM	Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women (Clinical Trials Arena)
Nov-21-24 08:00AM	Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 (Business Wire)
Nov-07-24 08:00AM	Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Nov-05-24 02:59AM	Two former Alexion leaders fight through a tough market to maintain a rare disease biotech (Pharma Voice)
Oct-29-24 08:00AM	Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT (Business Wire)
Sep-30-24 08:00AM	Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting (Business Wire) +5.88%
Sep-23-24 08:00AM	Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting (Business Wire)
Sep-10-24 08:00AM	Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit (Business Wire)
Sep-09-24 05:15PM	Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree (Business Wire)
Aug-29-24 08:00AM	Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis (Business Wire)
Aug-27-24 08:00AM	Rallybio to Present at Upcoming Investor Conferences (Business Wire) +8.77%
Aug-14-24 12:00PM	Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Aug-08-24 08:00AM	Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Jul-09-24 08:00AM	Rallybio to Present at the 2024 Jones Healthcare Seaside Summit (Business Wire)
Jun-17-24 08:00AM	Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations (Business Wire) -6.15%
May-31-24 07:00AM	3 Sorry Biotech Stocks to Sell in May While You Still Can (InvestorPlace) +5.03%
May-10-24 06:30AM	3 Biotech Stocks to Sell in May Before They Crash & Burn (InvestorPlace)
May-09-24 01:54PM	RLYB Stock Earnings: Rallybio Beats EPS for Q1 2024 (InvestorPlace)
10:14AM	Rallybio reins in preclinical R&D, while Monopar pivots to radiopharma to eke out cash (FierceBiotech.com)
08:00AM	Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
May-07-24 08:00AM	Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference (Business Wire)
Apr-17-24 04:01PM	FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting (Business Wire) -5.11%
Apr-12-24 10:23AM	RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up (Zacks) -26.17%
Apr-11-24 07:43AM	Why Is Rallybio (RLYB) Stock Up 93% Today? (InvestorPlace) +82.82%
Apr-10-24 04:01PM	Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) (Business Wire)
01:01PM	J&J, Rallybio partner on drug development for rare fetal condition (BioPharma Dive)
Apr-01-24 10:05AM	Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting (Business Wire)
Mar-12-24 08:00AM	Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) -8.70%
Feb-26-24 08:00AM	Rallybio to Present at the TD Cowen 44th Annual Health Care Conference (Business Wire) +5.88%
Feb-06-24 09:46AM	Rallybio, with financial fuel levels falling, loses 45% of workforce to extend cash runway into 2026 (FierceBiotech.com) +24.00%
08:00AM	Rallybio Announces Portfolio Prioritization and Provides Corporate Update (Business Wire)
Jan-04-24 08:00AM	Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024 (Business Wire)
Dec-20-23 08:00AM	Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 (Business Wire) -5.50%
Dec-09-23 12:00PM	Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting (Business Wire)
Nov-28-23 07:00AM	Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (Business Wire) -10.00%
Nov-09-23 08:00AM	Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Nov-08-23 08:00AM	Rallybio to Present at Upcoming Investor Conferences in November (Business Wire) -12.79%
Nov-02-23 09:15AM	Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting (Business Wire)
Oct-03-23 08:00AM	Rallybio to Present at the JonesTrading 2023 Healthcare Summit (Business Wire) +10.14%
Sep-03-23 12:00PM	Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 (Business Wire)
Aug-31-23 08:00AM	Rallybio to Present at Upcoming Investor Conferences in September (Business Wire)
Aug-08-23 08:00AM	Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Aug-02-23 08:00AM	Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference (Business Wire)
Jul-11-23 08:00AM	Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) (Business Wire)
Jun-29-23 07:00AM	Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023 (Business Wire) -5.57%
Jun-24-23 03:30PM	Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (Business Wire)
Jun-09-23 09:15AM	Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis (Business Wire)
Jun-01-23 08:00AM	Rallybio to Present at the Jefferies Healthcare Conference (Business Wire) +6.01%
May-29-23 09:55AM	Wall Street Analysts Believe Rallybio Corporation (RLYB) Could Rally 202.36%: Here's is How to Trade (Zacks)
May-12-23 09:55AM	Does Rallybio Corporation (RLYB) Have the Potential to Rally 290.63% as Wall Street Analysts Expect? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nash Christine A	Director	Oct 28 '26	Option Exercise	2.38	3,562	8,478	3,562	Oct 30 06:06 PM
Uden Stephen	Chief Executive Officer	Oct 27 '26	Option Exercise	6.08	33,244	202,124	148,864	Oct 29 05:20 PM
Lieber Jonathan I	Chief Financial Officer	Oct 27 '26	Sale	16.04	599	9,608	15,551	Oct 28 05:03 PM
Chung Wendy	Director	Oct 26 '26	Option Exercise	15.28	2,062	31,507	5,624	Oct 28 05:03 PM
Soteropoulos Paula	Director	Oct 16 '26	Option Exercise	2.38	3,562	8,478	6,544	Oct 20 05:32 PM
Boudreau Helen M	Director	Oct 16 '26	Option Exercise	15.28	2,062	31,507	8,604	Oct 20 05:29 PM
Hopfner Robert Lorne	Director	Oct 12 '26	Option Exercise	7.41	14,820	109,875	14,820	Oct 14 04:34 PM
Lieber Jonathan I	Chief Financial Officer	Oct 09 '26	Option Exercise	6.08	3,910	23,773	13,650	Oct 13 04:50 PM
Uden Stephen	Chief Executive Officer	Oct 06 '26	Option Exercise	6.08	22,456	136,532	115,620	Oct 08 05:04 PM
Lieber Jonathan I	Chief Financial Officer	Sep 29 '26	Option Exercise	6.08	5,000	30,400	9,740	Oct 01 05:32 PM
Liu Hui	Director	Sep 24 '26	Option Exercise	6.06	12,044	72,941	12,044	Sep 28 09:00 PM
Chung Wendy	Director	Sep 16 '26	Option Exercise	2.38	3,562	8,478	3,562	Sep 18 05:42 PM
Boudreau Helen M	Director	Jul 06 '26	Option Exercise	2.38	3,562	8,478	6,542	Jul 10 04:14 PM
ADAR1 Capital Management, LLC	10% Owner	May 19 '26	Buy	13.98	10,200	142,582	926,352	May 20 08:45 PM
ADAR1 Capital Management, LLC	10% Owner	May 18 '26	Buy	13.98	6,009	83,981	916,152	May 20 08:45 PM
ADAR1 Capital Management, LLC	10% Owner	May 13 '26	Buy	13.99	79,259	1,108,807	909,843	May 15 08:49 PM
ADAR1 Capital Management, LLC	10% Owner	May 15 '26	Buy	13.90	300	4,170	910,143	May 15 08:49 PM
ADAR1 Capital Management, LLC	10% Owner	May 11 '26	Buy	14.00	50,000	699,992	829,784	May 13 09:22 PM
ADAR1 Capital Management, LLC	10% Owner	May 12 '26	Buy	13.83	800	11,063	830,584	May 13 09:22 PM
ADAR1 Capital Management, LLC	10% Owner	May 04 '26	Buy	13.97	120,804	1,687,409	744,683	May 06 09:32 PM
ADAR1 Capital Management, LLC	10% Owner	May 05 '26	Buy	14.00	35,101	491,260	779,784	May 06 09:32 PM
Lieber Jonathan I	Chief Financial Officer	Feb 23 '26	Sale	5.06	789	3,992	4,115	Feb 23 06:21 PM

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Co-Founder & ChairmanDr. Martin W. MacKay Ph.D.

MBBSDr. Stephen Uden M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RLYB

Rallybio Corp

Upgrade your Finviz experience